Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan in Refractory Metastatic Colorectal Cancer
NCT06243393Phase 3Recruiting
- Sponsor
- Heidelberg University Hospital
- Start
- Apr 2024
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab govitecan in metastatic colorectal cancer (mCRC), sponsored by Heidelberg University Hospital. Started Apr 2024; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06243393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06243393.